Navarro's
Big Economic
Picture: Confusion
It’s
easy to be confused right now by this market – and lose a lot of
money. For example, the press reports that “the market” is at six
year highs. But they certainly don’t mean the NASDAQ exchange which
remains at around 2300 well off its 2000 peak of 5000. So if you are
speculating on techs, you are certainly not doing as well as speculators
focusing on S&P 500 and blue chip type plays.
The
confusion is a reflection of mixed economic signals. On the one hand,
the economy continues to grow robustly and reliable indices like the
ECRI suggest that 2006 will see continued growth. On the other hand, the
Fed inexorably continues its upward interest rate march threatening
contraction, and the list of shocks to the markets just keep on coming,
particularly in the energy markets.
In
fact, the oil supply chain has never looked to be in more peril than now
– at least since the 1970s. Rebel activity in Nigeria is all too real
as is labor strife in Norway. Civil war in Iraq is a real possibility.
It’s only a matter of time before terrorists make a direct hit on
Saudi production. Venezuela is a leftist tiger running propaganda
circles around the Bush Administration. Meanwhile, the new Fed Chairman
is making appropriate noises about the need to raise taxes or cut
spending to rein in the budget deficit, but neither option seems
political tenable and either would quickly lead to a slowdown.
This
makes the current market one for short term traders only or an arena to
play in with stocks that are largely outside the purview of the business
cycle. These include story
biotech stocks, “better mousetrap” disruptive technologies, and
so on.
This
Week's Market Movers
There
will be a considerable slowdown in data reports moving the markets this
week. The first biggie will be the PPI on Tuesday. The markets will be
looking for a confirmation of the same kind of softness viewed last week
with the CPI. An divergence on this point will pummel the bond market
and roil the stock market.
The
housing sector will be on the line once again with both new and existing
home sales come in on Thursday and Friday respectively. The Davio
column implies coming positive news
for the week to trigger a sector rebound. We’ll see.
Of
lesser and more long run interest will be the bankruptcy filings on
Monday. They’ve been going up because of changes in the bankruptcy
law. Let’s see if they stabilize – or whether credit card debt is
catching up with more and more Americans.
Portfolio Shorts and Pans
My
solar play ESLR picked off from Barron’s took a very heavy hit
on Friday from some profit-taking. I dumped my shares as a “cut your
losses” quickly risk management tool. I won’t look back, even if
that puppy bounces. I likewise dumped the rest of my HTI with a
small gain. The stock is simply too illiquid to feel comfortable about.
I
added to my ISIS position as it held $8 at the end of the week. I really
like the management of this company, and that is always a good start. As
I noted in
my daily blog, I also added CCC, a water filtration play on good
technicals (although it is not as liquid as I like – no pun intended).
I reloaded on STEM as it has been basing and is flashing buy signals
once again after a big drop some months ago.
I
am sitting underwater on a small position in VRX. I will wait and see on
this one as, based on a previous Vaino
biotech column, there are sound fundamental reasons to like the
stock. More broadly, this is a tough environment to make money in. Be
cautious, trim your losses quickly, and don’t be afraid to sit on
cash.

Davio's
Hedging Your Bets: Housing Bull
I
wanted to take a look at an issue that everyone and their great aunt
have been discussing for the past few years, Housing
Bubbles. I am in the camp that all asset classes get over- and
under-extended and in the long term, I believe that housing will revert
to a mean. There is clearly froth in many housing markets in the
US. There are also markets that are undervalued and offer opportunities
as an investor. As an arbitrager, my job is to decipher the static and
make a dynamic placement whether long or short in markets.
All
that being said, and “bearing” in mind my personal longer term
bearish outlook on the housing sector, I actually see the housing stocks
index (HGX) as a low risk bet on the long side over the next few months.
Let’s take a look at the chart and see why.

The
HGX chart shows me that a breakout in housing stocks took place on a
strong close this past Thursday, and you’ll see that where the chart
crossed through the thin red line. At the moment though, the index is
now a little overbought, but I would buy any dips that put the index
anywhere near $255-$265. I would continue to buy any weakness in housing
stocks until the old low near $250 is taken out. This is what we call
risk management. The shorter term favors the long traders here and
although my bearish macro-outlook in housing still persists, this
doesn’t mean we can’t break out the static from the dynamic and
benefit as speculators in the interim.

Vaino's Biotech Corner: unDIVERSAfying!
“Ultra-Thin”
enzyme is a novel, next-generation alpha amylase enzyme designed to
offer ethanol producers superior liquefaction performance. It works in
concert with other enzymes to efficiently convert the starch present in
corn into sugars that can then be processed into ethanol or other
value-added products such as high fructose corn sweetener. Ethanol
producers have traditionally used other alpha amylase enzymes that
operate at a sub-optimal pH, requiring costly process changes to adjust
the pH of the production process. Because “Ultra-Thin” enzyme is
capable of operating robustly at pH 4.5 – the same pH of the
production process – it can help producers to lower their operating
costs significantly. This enzyme has received FDA approval for use in
ethanol and sweetener production as well as additional applications.
Diversa Corporation
I
really like enzymes. They are Nature’s catalysts; and in my work, I
spend most of my days thinking of ways to make enzymes better. So do the
folks at Diversa (DVSA).
DVSA
started out in 1992 with a clever idea, to seek out enzymes that
function under extreme conditions, for example hot springs in
Yellowstone, and see if they could be applied to industrial processes
(enzymes can be finicky and often won’t work in a non-aqueous
environment or outside of a narrow temperature or pH range).
DVSA
had timing on its side; they went public in February 2000 and raised
$200M. The stock did pretty well, closing at nearly $150 two weeks after
its IPO. Unfortunately, with all the hubris associated with the biotech
industry at the turn of the century, a lot of newly public companies
started believing their own press and got greedy – and DVSA was no
different.
In
this instance, DVSA decided that it wasn’t just good at engineering
enzymes. It was also good at drug discovery. So DVSA set up a drug
discovery effort and even licensed-in an anti-fungal lead compound from
GSK. The Market punishes such arrogance, and DVSA went on a severe,
multi-year downward slide. Indeed, just six months ago DVSA was
trading for a measly five bucks, 97% lower than its exuberant peak.
Now,
the stock has bounced back to the $8 range these last few weeks, and I
think with good reason. DVSA’s CEO resigned late last year under
pressure, and the company is finally restructuring, getting out of
businesses it never should have gotten into in the first place. DVSA
also recently announced FDA approval of their “Ultra-Thin” enzyme.
As the introductory excerpt from the corporation, this is an amylase or
digestive enzyme that will make creating ethanol a lot easier and
cheaper.
Diversa
should, then, be able to leverage the current oil situation and the
President’s calling for greater use of ethanol as fuel to its
advantage. GM’s “Live Green-Go Yellow” ad campaign to sell its
flex-fuel vehicles that can run on either gasoline or ethanol can’t
hurt either.
NYBOT
recently introduced futures and options trading for sugar-derived
ethanol and CBOT will follow with futures contracts for corn-based
ethanol later this year. From a practical point of view, ethanol won’t
even make a dent in our oil consumption: but that doesn’t matter. The
politics of ethanol will give members of Congress from Iowa and Nebraska
the ability to get huge ethanol producing plants built in their states.
New ethanol plants will want to use the best catalysts possible, and,
right now, I think DVSA’s Ultra-Thin is it.
A
big note of caution: DVSA isn’t going to be an overnight success. I
listened in on their earnings call three weeks ago, and they are
anticipating revenue of ~$20M for their Ultra-Thin enzyme for 2006.
DVSA predicted it will be profitable in 2007, and there is a chance
they’re correct. I think DVSA is a good long term (2 yrs) buy.
However, I am concerned that DVSA has underestimated their restructuring
costs and the stock is going to get hit the day after the next few
earnings reports and recover in the following weeks. That’s a buying
opportunity.
|

|
Peter
Navarro is a business professor at the University of California
and the author of the best-selling investment book
If It's
Raining
in Brazil, Buy Starbucks. His latest book is
The
Well-Timed Strategy |
|

|
Matt
Davio is a managing partner at the hedge fund,
Red Rock Capital Fund.
Catch
his Daily
Blog as PeterNavarro.com
|
|

|
Andrew
Vaino is a Ph.D. chemist who spent two years at
The Scripps Research Institute in La Jolla, CA, working in the
laboratories of Nobel-Laureate Barry Sharpless and Kim Janda. He
currently teaches at The University of Maine, where his research
group is focused on exploring the interface between enzymology,
organic chemistry, and nanotechnology. |
© 2006
Peter Navarro
www.peternavarro.com
Editorial Archive
CONTACT
INFORMATION
Peter Navarro
Irvine, California USA
Email
| Website
DISCLAIMER:
This newsletter is written for educational purposes only. By no means do
any of its contents recommend, advocate or urge the buying, selling, or
holding of any financial instrument whatsoever. Trading and investing
involves high levels of risk. The authors express personal opinions and
will not assume any responsibility whatsoever for the actions of the
reader. The authors may or may not have positions in the financial
instruments discussed in this newsletter. Future results can be
dramatically different from the opinions expressed herein. Past
performance does not guarantee future performance.
Disclaimer
|